EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Research Progress on the ARHGEF Family in Cardiovascular Diseases

Hong Zhang iD, Qihao Guo, Benson Peter Mugaka, Guangjie Tai, Ming Xu

Cell Biochemistry and Function · 2026-07 · 44 (7)

DOI: 10.1002/cbf.70266 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, online erschienen am 14.07.2026. Verfasst von Hong Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Rho Guanine Nucleotide Exchange Factors, Cardiovascular Diseases. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ARHGEF (Rho guanine nucleotide exchange factor) family acts as a key upstream regulator of Rho GTPases, including RhoA, Rac1, and Cdc42. It plays critical roles in cytoskeletal remodeling, cell migration, vascular tone regulation, and inflammatory responses. Recent studies have shown that dysregulated ARHGEF activity contributes to cardiovascular diseases such as atherosclerosis, hypertension, cardiac hypertrophy, fibrosis, and myocardial ischemia/reperfusion injury. However, the functions of ARHGEFs in specific cell types and their overall signaling mechanisms in the cardiovascular system remain poorly understood. This review provides a comprehensive framework of current progress in understanding the molecular mechanisms underlying ARHGEF‐mediated regulation in endothelial dysfunction, vascular remodeling, myocardial fibrosis, and ischemia/reperfusion injury. It also highlights potential pharmacological strategies that target the ARHGEF and Rho GTPase signaling axis for precise therapeutic intervention. By integrating molecular, cellular, and translational research, this work offers a conceptual framework for ARHGEF‐driven signaling in cardiovascular diseases, and offers new insights for future drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rho Guanine Nucleotide Exchange FactorsCardiovascular DiseasesHumansAnimalsSignal Transductionrho GTP-Binding Proteins

Stichwörter der Autor:innen

Rho GTPaseRho guanine nucleotide exchange factorsatherosclerosiscardiomyopathyhypertensionmyocardial ischemia/reperfusion

Substanzen

Rho Guanine Nucleotide Exchange Factorsrho GTP-Binding Proteins

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Natural Products Development and Formulation, Institute of Traditional Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

ORCID-Profile: Hong Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, H., Guo, Q., Mugaka, B. P., Tai, G., & Xu, M. (2026). Research Progress on the ARHGEF Family in Cardiovascular Diseases. Cell Biochemistry and Function, 44(7). https://doi.org/10.1002/cbf.70266

Vancouver

Zhang H, Guo Q, Mugaka BP, Tai G, Xu M. Research Progress on the ARHGEF Family in Cardiovascular Diseases. Cell Biochemistry and Function. 2026;44(7). doi:10.1002/cbf.70266

BibTeX
@article{Zhang2026,
  author = {Zhang, Hong and Guo, Qihao and Mugaka, Benson Peter and Tai, Guangjie and Xu, Ming},
  title = {Research Progress on the ARHGEF Family in Cardiovascular Diseases},
  journal = {Cell Biochemistry and Function},
  year = {2026},
  volume = {44},
  number = {7},
  doi = {10.1002/cbf.70266}
}
Kostenlos starten →